drugset / Trial / NCT04575558
HOPE: A Trial of Hydroxichloroquine Plus Azithromycin in High Risk COVID-19
RandomizedParallel-groupDouble-blindTreatment
Summary
Multicenter, double blind, randomized clinical trial for high-risk patients over 18 years of age, symptomatic for COVID-19 infection, without any severity criteria
Timeline
- Start
- 2020-06-30
- Primary completion
- 2020-09-01
- Completion
- 2020-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azithromycin | Small molecule | 500 mg | Oral |
| Background | Hydroxychloroquine | Small molecule | 400 mg | Oral |